Osteoarthritis of the knee is a leading cause of pain and disability, affecting millions of people worldwide. Excess body weight increases the mechanical load on the knee joint, accelerating cartilage breakdown and inflammation.
While diet and exercise remain the most effective form of weight management, a new class of weight loss medications, such as semaglutide, could also help.
Recent clinical research suggests that these medications may offer a substantial reduction in arthritic knee pain.
Here we’ll explore why weight loss matters when you have osteoarthritis, and whether weight loss medications are worth trying.
Why weight loss matters in knee osteoarthritis
Every extra kilogram of body weight places additional stress on the knee with each step, increasing the risk of cartilage injury and inflammation. Over time, this cumulative load contributes to the development and progression of osteoarthritis.
Studies have shown that even modest weight loss can translate into meaningful pain relief and improved function. For example, according to OARSI guidelines, shedding 5-10% of body weight can reduce knee pain by up to 20% and slow joint degeneration.
However, achieving and sustaining significant weight loss through lifestyle changes alone can be challenging. Many patients struggle with plateauing weight despite rigorous diet and exercise programs.
This is where weight loss medications can play a supportive role, helping patients overcome barriers and achieve the level of weight reduction needed to protect their joints.
The role of weight loss medications in reducing arthritic knee pain
GLP-1 receptor agonists such as Semiglutide, originally developed for type 2 diabetes, work by improving insulin secretion, slowing gastric emptying, and promoting satiety.
Semaglutide (marketed as Ozempic or Wegovy) is administered once weekly and has been shown to produce average weight reductions of 13.7% over 68 weeks in patients with obesity. In the recently published STEP 9 trial, 407 participants with a body-mass index (BMI) of 30 or higher and moderate-to-severe knee osteoarthritis were randomly assigned to receive either semaglutide 2.4 mg or placebo, alongside dietary and exercise counselling. By week 68, those on semaglutide lost an average of 13.7% of their body weight compared to 3.2% in the placebo group, and experienced a greater reduction in knee pain.
These findings suggest that semaglutide not only helps patients lose weight but also delivers clinically meaningful pain relief, likely driven by reduced joint loading and systemic inflammation.
Integrating weight loss medications into patient care
While the recent trial offers compelling evidence, GLP-1 receptor agonists are not a universal solution. Ideal candidates are patients with a BMI of 30 or above (or 27 with obesity-related comorbidities), who have struggled to achieve adequate weight loss through diet and exercise alone.
Before initiating therapy, it’s important to discuss potential benefits and risks, including gastrointestinal side effects and cost considerations.
Medication should complement, not replace, lifestyle interventions. A tailored physical therapy program remains essential to strengthen the muscles around the knee, improve flexibility, and correct gait mechanics. Also, maintaining a balanced, nutrient-rich diet, and staying hydrated, further support joint health and overall wellbeing.
Personalised treatment for knee pain
The current research shows that for those with knee osteoarthritis, new medications like semaglutide offer an additional avenue to relieve pain, improve function, and potentially slow disease progression. While long-term studies are still needed to confirm effects on joint structure, current evidence supports their use as part of a comprehensive treatment plan.
Patients should work closely with their orthopaedic surgeon to determine if weight loss medication is appropriate for them. If you’re struggling with knee pain, schedule an appointment with Mr Shah Punwar for personalised treatment and management advice.
